Brofaromine

Brofaromine
Systematic (IUPAC) name
4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine
Clinical data
Routes of
administration		 Oral
Legal status
  • ℞ (Prescription only)
Pharmacokinetic data
Protein binding 98%
Biological half-life 9-14 hours
Identifiers
CAS Number 63638-91-5 YesY
ATC code none
PubChem CID 44571
ChemSpider 40549 YesY
UNII 6WV4B8Q07H YesY
KEGG D02560 YesY
ChEMBL CHEMBL160347 YesY
Chemical data
Formula C14H16BrNO2
Molar mass 310.186 g/mol
  (verify)

Brofaromine (proposed brand name Consonar) is a reversible inhibitor of monoamine oxidase A (RIMA) discovered by Ciba-Geigy.[1] The compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market.[2]

Brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants.

Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

References

  1. ↑ US Patent 4210655
  2. ↑ Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483. Free full text



This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.